Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake.

OBJECTIVES In this study, the impact of noninsulin-dependent type 2 diabetes mellitus on carotid wall (18)F-fluorodeoxyglucose (FDG) uptake in patients with documented or suspected cardiovascular disease was evaluated. BACKGROUND Inflammation is a pivotal process in the progression of atherosclerosis, which can be noninvasively imaged by FDG positron emission tomography (FDG-PET). METHODS Carotid artery wall FDG uptake was quantified in 134 patients (age 60.2 ± 9.7 years; diabetic subjects, n = 43). The pre-scan glucose (gluc) level corrected mean of the maximum standardized uptake value (SUV) values ((mean)SUV(gluc)), mean of the maximum target-to-background ratio ((mean)TBR(gluc)), and single hottest segment (SHS(gluc)) of FDG uptake in the artery wall were calculated. Associations between FDG uptake, the presence of risk factors for atherosclerosis, and diabetes were then assessed by multiple regression analysis with backward elimination. RESULTS The study demonstrated a significant association between diabetes and FDG uptake in the arterial wall (diabetes (mean)SUV(gluc) β = 0.324, (mean)TBR(gluc) β = 0.317, and SHS(gluc) β = 0.298; for all, p < 0.0001). In addition, in diabetic patients, both body mass index ≥ 30 kg/m(2) ((mean)SUV(gluc) β = 0.4, (mean)TBR(gluc) β = 0.357, and SHS(gluc) β = 0.388; for all, p < 0.015) and smoking ((mean)TBR(gluc), β = 0.312; SHS(gluc), β = 0.324; for all, p < 0.04) were significantly associated with FDG uptake. CONCLUSIONS Type 2 diabetes was significantly associated with carotid wall FDG uptake in patients with known or suspected cardiovascular disease. In diabetic patients, obesity and smoking add to the risk of increased FDG uptake values.

[1]  J. Pickup.  Inflammatory markers and type 2 diabetes. , 2006, Diabetes technology & therapeutics.

[2]  B. Hutton,et al.  Vascular Inflammation Imaging with 18F-FDG PET/CT: When to Image? , 2009, Journal of Nuclear Medicine.

[3]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[5]  J. Shaw,et al.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[6]  Ahmed Tawakol,et al.  Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography , 2005, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[7]  B. Kahn,et al.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.

[8]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[9]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[10]  M. Reiser,et al.  18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease , 2009, Journal of Nuclear Medicine.

[11]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[12]  A. Ceriello.  New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. , 2003, Diabetes care.

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  O. Prante,et al.  Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  J. Staessen,et al.  Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations , 2011, Hypertension Research.

[16]  R L Wahl,et al.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. , 1992, Radiology.

[17]  Sungeun Kim,et al.  Vascular Inflammation in Patients With Impaired Glucose Tolerance and Type 2 Diabetes: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography , 2010, Circulation. Cardiovascular imaging.

[18]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[19]  E. Rota Kops,et al.  The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  H. Sillesen,et al.  Gene expression and 18FDG uptake in atherosclerotic carotid plaques , 2010, Nuclear medicine communications.

[21]  S. Wild,et al.  Glycemic control and cardiovascular disease in Type 2 diabetes: a review , 1999, Diabetes/metabolism research and reviews.

[22]  V. Fuster,et al.  Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study , 2009, Circulation. Cardiovascular imaging.

[23]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[24]  Kazuomi Kario,et al.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. , 2008, American journal of hypertension.

[25]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Z. Fayad,et al.  Vascular Imaging with 18F-FDG PET/CT: Optimal 18F-FDG Circulation Time? , 2009, Journal of Nuclear Medicine.

[27]  R. R. Hocking.  The analysis and selection of variables in linear regression , 1976 .

[28]  N. Draper,et al.  Applied Regression Analysis , 1966 .

[29]  S. Libutti,et al.  Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. , 2008, Nuclear medicine and biology.

[30]  Norman R. Draper,et al.  Applied regression analysis (2. ed.) , 1981, Wiley series in probability and mathematical statistics.